Questcor gets approval for 77% cut in Medicaid rebate for MS drug Acthar Gel

(Reuters) – Questcor Pharmaceuticals Inc said it is now eligible to provide lower Medicaid rebates on its flagship multiple sclerosis drug, Acthar Gel, allowing for improved financial results in the future.

The company said the government informed it that Acthar is now eligible for lower rebates for patients under Medicaid — the program that funds medical and health-related services for the poor and disabled.

In a filing, Questcor said it estimates the rebate rate to be cut from about 100 percent of the amount it charges its distributor to 23.1 percent, and that the cut could be materially positive to its financial results.

Acthar, the only drug Questcor sells, has been approved to treat a range of disorders including multiple sclerosis, rheumatic disorders, allergies, seizures in babies, a kidney condition called nephrotic syndrome, and eye and respiratory diseases.

(Vidya P L Nathan in Bangalore, Editing by Anthony Kurian)

We appreciate commenting on our stories.

 Please note that all comments are moderated. 

LIKE this Blog by clicking the LIKE button – top left

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~